DPYD Testing Before — 5-FU and Capecitabine

Without testing, there is no way to know you carry the variant before you react. In patients with significant DPD deficiency, a standard dose of 5-FU or capecitabine can cause severe toxicity affecting the gut lining, mouth, bone marrow, and nervous system. Some of these reactions are life-threatening and can begin with the first infusion. The value of testing is that it identifies this risk before any dose is given, when it can still change the plan.

The honest answer is that population data for Indian patients is much thinner than for European populations, and reliable figures specific to South Asian ancestry are not yet established. CPIC guidance acknowledges that variant frequencies differ between populations. What is consistent across populations studied is that DPYD variants do occur. Your oncologist can discuss what is currently understood about risk and whether that changes the case for testing in your situation.

Not automatically. A result showing partial DPD deficiency does not rule out the drug — it changes the conversation about how to proceed, which is a decision for your oncologist. Complete deficiency is a different situation, and your team will weigh whether the drug should be used at all. Bring the result to your oncologist and ask what it means for your specific plan. This page carries no dose or dose-adjustment guidance.

Genotyping panels generally return results within one to two weeks, though turnaround varies by laboratory. Ask when the test is requested — not after. If your first infusion is already booked within days, tell your team immediately so they can factor the timeline into the schedule. Planning ahead is the part you can control.

Coverage varies between insurers and there is no universal rule. Ask your insurer directly whether pharmacogenomic testing is included under your policy. If cost is a concern, ask your oncologist or the hospital's patient services team — they will know which laboratories charge what and whether any subsidised options are available through your centre.

5-FU and capecitabine are among the most widely used chemotherapy drugs across oncology. They appear in regimens for colorectal cancer, gastric cancer, oesophageal cancer, breast cancer, and certain head and neck cancers, among others. They are also given as part of combination regimens you may recognise by name. If your plan includes either drug in any form, the DPYD question applies to you. Check with your oncologist if you are unsure whether your regimen contains a fluoropyrimidine.

Genotyping sequences the DPYD gene to look for known variants. Phenotyping measures how well your body actually processes the drug's building blocks — typically by checking the level of uracil in your blood before treatment. Both approaches identify DPD deficiency, and CPIC supports both. In India, genotyping is the test more likely to be accessible at this time. Ask your oncologist which approach is available at your centre and what it would cover.

That is a clinical decision for your oncologist, not something this page can answer. Your oncologist will weigh the cancer being treated, the available options, the urgency of starting, and the limits of what testing can be accessed. What you should do is ask the question directly: tell your team you know about DPYD testing and want to understand what the plan is if it cannot be done. That is always a reasonable question to raise, and your team should be able to explain their reasoning.